Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medinol Adopts “Trojan Horse” Strategy To Beat Drug-Eluting Stents

This article was originally published in The Gray Sheet

Executive Summary

Medinol will begin pilot clinical trials by the end of 2002 on an anti-restenosis drug delivery technology intended as an alternative to drug-eluting stents

You may also be interested in...



Medtronic Broadens Drug Delivery Options With EndoBionics Purchase

Medtronic's equity investment in privately held EndoBionics for injectable drug delivery technology complements Medtronic's existing drug-eluting stent platform

Medtronic Broadens Drug Delivery Options With EndoBionics Purchase

Medtronic's equity investment in privately held EndoBionics for injectable drug delivery technology complements Medtronic's existing drug-eluting stent platform

FDA Panel Review Of J&J Cypher Stent Will Weigh SIRIUS Late Loss Data

Johnson & Johnson/Cordis' upcoming presentation before an FDA advisory panel on the Cypher drug-eluting stent will highlight a 67% reduction of target vessel failure (TVF) at nine months compared with bare stents

Related Content

UsernamePublicRestriction

Register

MT017306

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel